Overview

Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris

Status:
Completed
Trial end date:
2013-05-05
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of dapsone in subjects with acne vulgaris following 28 days of dosing.
Phase:
Phase 1
Details
Lead Sponsor:
Allergan
Treatments:
Dapsone